Karuna Therapeutics Inc 's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Karuna Therapeutics Inc 's ROA in the fourth quarter of 2023?
Karuna Therapeutics Inc recorded a cumulative net loss of $-434 million during 12 months ending in the fourth quarter of 2023, resulting in a negative return on assets (ROA) of -27.08%.

However, within the Healthcare sector 479 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2023 quarter, so far to 4066, from total ROA ranking in the third quarter of 2023 at 4084.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter
Y / Y Total Assets Change	77.9 %	12.05 %	240.48 %	222.92 %	121.27 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-434	-396	-354	-316	-276
Return On Assets (TTM)	-27.08 %	-28.79 %	-26.44 %	-29.19 %	-33.69 %
KRTX's Total Ranking	# 4066	# 4084	# 4274	# 5052	# 4559
Total Assets (TTM) in million	2,062	1,372	1,458	1,513	1,159
Seq. Total Assets Change	50.26 %	-5.9 %	-3.66 %	30.59 %	-5.36 %
Seq. Net Income Change	-	-	-	-	-

KRTX's 5 Years Annual ROA >> Back to KRTX Management Effectiveness >> Compare KRTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 196
Sector	# 480
Overall	# 4035

Return On Assets Statistics
High	Average	Low
-12.84 %	-25.91 %	-40.91 %
(Jun 30 2020)		(Jun 30 2022)

Financial Statements
Karuna Therapeutics Inc 's Assets	$ 2,062 million	KRTX's Balance sheet
Karuna Therapeutics Inc 's Income	$ -114 million	Quarterly KRTX's Income Statement
KRTX's Income by Division		See KRTX's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	77.75 %	122.46 %	50.68 %	-11.95 %	-
Total Assets in million	2,062	1,160	521	346	393
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-434	-276	-144	-69	-44
Annual Return On Assets	-21.03 %	-23.82 %	-27.58 %	-19.81 %	-11.18 %

KRTX's 5 Years Annual ROA >> Back to KRTX Management Effectiveness >> Compare KRTX ROA to its Competitors

More Return On Assets Ratios
KRTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KRTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KRTX's Competitors
Subscribers only: Roa for Karuna Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for KRTX's Customers

You may also want to know
KRTX's Roi	KRTX's Inventory Turnover Ratio	KRTX's Growth Rates	KRTX's Dividend Comparisons
	KRTX's Profitability Ratios	KRTX's Asset Turnover Ratio	KRTX's Dividend Growth
KRTX's Roe	KRTX's Valuation Ratios	KRTX's Financial Strength Ratios	KRTX's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.